GET DAILY SIGNALSCallan JMB (CJMB) Shares Drop -86% in 30 Days Amid Delisting and Deal Setbacks
Key Takeaways
- CJMB shares have fallen roughly 86% over the last 30 days, sliding from a $2.44 close on October 2 to about $0.33, leaving the micro-cap near its 52-week low.
- The decline was driven primarily by a Nasdaq delisting determination tied to a failed minimum stockholders' equity requirement and the company's subsequent appeal to a Nasdaq Hearings Panel.
- Callan JMB's termination of a previously announced $48 million oil and gas acquisition removed a key growth path and triggered a sharp single-day selloff.
- A new $16 million IV-bag manufacturing plan projecting $450 million in annual revenue was met with skepticism given the company's roughly $5 million in trailing revenue and recurring losses.
- Persistent operating losses and a market capitalization of only a few million dollars continue to pressure investor sentiment and liquidity.
- For additional data, explore the ticker's Price Targets, Earnings, and Forecast pages.
- Interested in automated trading strategies? Explore Trending AI Robots.
Callan JMB (CJMB) Business Overview
Callan JMB Inc. (NASDAQ: CJMB) operates as a vertically integrated logistics and fulfillment firm focused on thermal-management and cold-chain solutions for the life sciences sector via its Coldchain Technology Services subsidiary. It combines specialized packaging, monitoring tech, and expertise to handle frozen shipping for cell therapies, vaccines, stem cells, and other sensitive materials, while also providing emergency preparedness services. The company has explored moves into oil and gas development and pharmaceutical manufacturing.
Founded in 2006 and based in Spring Branch, Texas, it went public in February 2025 at $4.00 per share. From what I see, its small revenue base and ongoing losses keep it squarely in the high-risk micro-cap category despite the niche market exposure.
CJMB Stock Performance Over the Past 30 Days and Quarter
Over the last 30 days, CJMB has declined approximately 86%, falling from a closing price of $2.44 on October 2 to roughly $0.33 as of early November. The drop concentrated in key sessions, including a roughly 65% decline on October 20 alone, with further weakness into late October and early November.
The quarterly picture shows a similar reversal. After trading near $0.75 in early July, the stock rallied to a mid-August peak around $2.72 before drifting in the $2.00–$2.50 range through September. From early August levels near $1.66, it is now down roughly 80%.
Key Drivers Behind the Recent 30-Day Decline
The primary catalyst was Nasdaq's listing determination. On October 12, staff ruled that the company had not met the terms of an extension for the $2.5 million minimum stockholders' equity requirement, prompting an appeal to a Nasdaq Hearings Panel on October 14. This stayed a planned trading suspension but left delisting risk intact. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Adding to the pressure, an 8-K filing disclosed termination of the asset purchase agreement with The Pfanenstiel Company, ending the previously announced $48 million oil and gas deal after due diligence concerns. This removed a potential growth avenue and coincided with heavy selling. Separately, the company announced blueprint approval for a $16 million IV-bag facility in Alabama with projections of up to $450 million in annual revenue—roughly 90 times trailing revenue—which drew market skepticism.
Quarterly Performance Drivers and Sentiment Shift
August brought a rally on regained Nasdaq bid-price compliance and progress on strategic moves, including the proposed oil and gas transaction. However, the failure to meet the equity compliance deadline by October shifted focus to listing risks. Termination of the oil and gas deal and questions around funding for manufacturing plans reinforced concerns over execution and potential dilution from the shelf registration. With trailing revenue near $5 million, a 2025 net loss of roughly $8 million, and market value in the low single-digit millions, the stock remains sensitive to sharp moves.
What to Watch for CJMB Going Forward
The Nasdaq Hearings Panel outcome remains the key near-term driver, determining whether the stock stays listed or faces suspension. I’m watching this closely alongside any capital raise that could restore at least $2.5 million in stockholders' equity, potential dilution effects, and progress on the IV-bag facility financing and construction. Updated contracts, revenue guidance, and efforts to reduce operating losses will also matter more than the company’s own large revenue projections in shaping the outlook.
Using Tickeron AI Tools for Research
In my analysis of volatile names like this, I often review Tickeron’s Trending AI Robots page to explore automated strategies across different market conditions and timeframes. The section highlights top-performing bots from hundreds available, allowing a data-driven look at systematic approaches without needing to build them from scratch. It gives a practical way to evaluate how various AI-driven bots have performed on similar micro-cap situations.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CJMB's RSI Oscillator is remaining in oversold zone for 9 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +12.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where CJMB advanced for three days, in 53 of 65 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
CJMB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CJMB as a result. In 34 of 36 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for CJMB turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 14 similar instances when the indicator turned negative. In 13 of the 14 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
CJMB moved below its 50-day moving average on October 16, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CJMB crossed bearishly below the 50-day moving average on October 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 5 of 5 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CJMB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CJMB entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.428) is normal, around the industry mean (2.670). P/E Ratio (-0.176) is within average values for comparable stocks, (7.462). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.110). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (2.202) is also within normal values, averaging (2.034).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. CJMB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CJMB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry OtherTransportation
Advertisement